Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|April 15, 2015
Laser Printing Technology Marks a Range of Materials
Domino Printing's F220i Fiber Laser technology has the flexibility to print permanent high-quality codes on a variety of materials.
Domino Printing's F220i Fiber Laser technology has the flexibility to print permanent high-quality codes on a variety of materials to meet strict industry requirements, such as guidelines placed by the Drug Quality and Security Act (DQSA) and the FDA’s Unique Device Identification (UDI) system. Designed to code materials that typically aren’t suitable for CO2 laser technology-such as metals, plastics and certain films-the F220i Fiber Laser broadens the range of products that can be marked. This new flexibility is particularly important to the medical device sector, as many companies seek solutions to comply with the FDA’s UDI system which, over the next seven years, will require all medical devices to be labeled with human and machine readable identifiers through distribution and use, the company said in a press release.
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
3
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
4
PharmTech’s Weekly Roundup—September 25, 2026
5